NASDAQ:MDWD

Mediwound Stock News

Healthcare > Biotechnology

Buy MDWD

*Your capital is at risk

$14.12

+0.0200 (+0.142%)

At Close: Jul 31, 2026

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

08:00am, Monday, 03'rd Mar 2025

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its f

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

08:00am, Tuesday, 25'th Feb 2025

Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burns NexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, I

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

08:00am, Monday, 24'th Feb 2025

YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Office

MediWound to launch Phase III trial for venous leg ulcers

08:12am, Wednesday, 12'th Feb 2025

MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

07:00am, Wednesday, 12'th Feb 2025

Phase III trial to assess the efficacy and safety of EscharEx ® for debridement and facilitation of active wound closure

MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

07:36am, Monday, 27'th Jan 2025

MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

01:46pm, Tuesday, 26'th Nov 2024

MediWound Ltd. (NASDAQ:MDWD ) Q3 2024 Earnings Conference Call November 26, 2024 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg -

MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates

09:16am, Tuesday, 26'th Nov 2024

MediWound (MDWD) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.24 per share a year ago.

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

07:00am, Tuesday, 26'th Nov 2024

EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC

MediWound Is A Healthy Investment

10:49am, Tuesday, 29'th Oct 2024

MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles,

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

07:00am, Thursday, 10'th Oct 2024

Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

04:15pm, Thursday, 15'th Aug 2024

Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by